Search Results | MSF Science Portal

Science Portal

v2.1.5655.produseast1

About MSF Science Portal

About

Frequently Asked Questions (FAQs)

v2.1.5655.produseast1

Showing 1 - 8 of 8 Items

Sort By: Relevance

Newest to oldest
Oldest to newest
Relevance

Journal Article

Research

Safety of hepatitis E vaccine in pregnancy: an emulated target trial following a mass reactive vaccination campaign in Bentiu internally displaced persons camp, South Sudan

Nesbitt RC, Azman AS, Asilaza VK, Edwards JK, Gitahi P, et al.

2024-11-01 • Lancet Global Health

Conference Material

Slide Presentation

Safety of hepatitis E vaccine in pregnancy: emulating a target trial following a mass reactive vaccination campaign in South Sudan

Nesbitt R, Azman AS, Asilaza VK, Edwards JK, Nkemenang P, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

Abstract

Safety of hepatitis E vaccine in pregnancy: emulating a target trial following a mass reactive vaccination campaign in South Sudan

Nesbitt R, Azman AS, Asilaza VK, Edwards JK, Nkemenang P, et al.

2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION

Hepatitis E causes high mortality among pregnant women, with case fatality risks over 30% and adverse fetal outcomes. There is an evidence gap on the safety of the ...

Journal Article

Research

Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan

Nesbitt RC, Asilaza VK, Gignoux EM, Koyuncu A, Gitahi P, et al.

2024-01-22 • PLOS Neglected Tropical Diseases

INTRODUCTION

Hepatitis E (HEV) genotypes 1 and 2 are the common cause of jaundice and acute viral hepatitis that can cause large-scale outbreaks. HEV infection...

Conference Material

Abstract

Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against hepatitis E in Bentiu, South Sudan

Nesbitt RC, Rumunu J, Asilaza VK, Gitahi P, Nkemenang P, et al.

2023-06-07 • MSF Scientific Day International 2023

INTRODUCTION
A three-dose recombinant vaccine against hepatitis E, Hecolin, has been licensed for use in China since 2011. While not recommended for routine use due to lack of eviden...

Conference Material

Poster